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Abstract
Context:
Takotsubo translates to “octopus pot” in Japanese. Takotsubo cardiomyopathy (TTC) is characterized by a
transient regional systolic dysfunction of the left ventricle. Catecholamine excess is the one most studied
and favored theories explaining the pathophysiology of TTC.
Case Report:
We present the case of a 52-year-old Hispanic female admitted for venlafaxine-induced TTC with a review
literature on all the cases of Serotonin–norepinephrine reuptake inhibitors (SNRI)-associated TTC published
so far.
Conclusion:
SNRI inhibit the reuptake of catecholamines into the presynaptic neuron, resulting in a net gain in the
concentration of epinephrine and serotonin in the neuronal synapses and causing iatrogenic catecholamine
excess, ultimately leading to TTC.
Keywords: Apical ballooning syndrome, selective serotonin-norepinephrine reuptake inhibitors, stress-
induced cardiomyopathy, Takotsubo cardiomyopathy
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Takotsubo cardiomyopathy (TTC) is a temporary condition that results due to sudden weakening of the
heart muscle and change in the shape of the left ventricle. The left ventricle changes its shape developing a
narrow neck and a round bottom, hence the name Takotsubo, which means “octopus pot” in Japanese. Other
synonyms are stress-induced cardiomyopathy, broken-heart syndrome, and apical ballooning syndrome.
Although the etiological mechanism of TTC remains unclear, a dramatic increase in catecholamines, such as
epinephrine and norepinephrine, has been recognized as a possible cause. Selective serotonin-
norepinephrine reuptake inhibitors (SNRI) such as venlafaxine, desvenlafaxine, and duloxetine inhibit
reuptake of serotonin and norepinephrine at presynaptic level and increase their level at postsynaptic level,
predisposing the patients to iatrogenic catecholamine excess. We report a case of TTC following normal
dosing of venlafaxine, and review all the cases reported of TTC associated with SNRI use.
Case Report
A 52-year-old Hispanic female presented to the Emergency Room with complain of left-sided chest pain
radiating to her left arm associated with nausea but no vomiting. According to the patient, the pain began 2
hours before presentation when she was having breakfast; she reported no previous similar episodes. She did
not recall any change in her daily routine and had no stress at work or home. Her past medical history
included hypertension, for which she was taking enalapril 2.5 mg, and chronic back pain secondary to disc
budge at L4–L5 level, for which she was taking oxycodone. She never had any cardiac catheterization or
echocardiography done in past. She had no known drug or food allergies. She was recently started on
venlafaxine 75 mg for her depression 4 weeks ago. Upon arrival to the Emergency Department, her blood
pressure was 128/85 with a pulse of 94 beats per minute. The physical examination including cardiovascular
examination was essentially normal. Electrocardiography done in the emergency department showed sinus
tachycardia with rate of 118/min with no ST segment changes but diffuse symmetric T-wave inversions in
the limb and precordial leads [Figure 1]. Patient was given Asprin (ASA) 325 mg, plavix loading dose of
600 mg, and nitroglycerin with some improvement in chest pain. Her cardiac biomarkers were increased at
1.85 ng/ml. Patient was diagnosed with non-ST elevation myocardial infarction, admitted to telemetry floor,
and started on heparin drip. Her chest pain improved overnight and troponins in morning were 1.7 ng/ml,
with normal complete blood count and metabolic profile. Patient was taken for cardiac catheterization,
which showed normal coronaries [Figure 2], with left ventriculogram in right anterior oblique projection
showing diffuse dyskinesis/ballooning of the left ventricular apex (both anterior and inferior aspects) and
ejection fraction of 45% [Figure 3 panel A/B]. Echocardiography was also done that showed hyperkinesia
of the basal segment of the left ventricle with akinesis and ballooning of the apical segment of the left
ventricle, with ejection consistent with the morphology of TTC [Figure 4 panel A/B].
Patient was diagnosed to have TTC secondary to SNRI venlafaxine. She was discharged home on ASA,
enalapril, and metoprolol, and was asked to discontinue venlafaxine therapy. Follow-up echocardiography
after 6 weeks showed complete resolution of wall motion abnormalities and normal ejection fraction.
Discussion
TTC was first reported in 1990, and since then many cases have been reported and various theories have
been put forward to explain its pathophysiology. TTC is characterized by reversible left ventricular
dysfunction due to akinesia/hypokinesia involving the apical/mid-ventricular segments and a hyperactive
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base (causing left ventricular outflow obstruction). Patients usually present with chest pain, dyspnea, and
syncope. They may have ST segment/T-wave changes with modest elevation of troponins. Diagnosis is
confirmed with an echocardiography showing regional wall abnormalities that extend beyond a single
epicardial coronary artery distribution and cardiac catheterization showing absence of obstructive coronary
disease or angiographic evidence of acute plaque rupture.[1] With conservative management and supportive
treatment, most of the cases show recovery of left ventricular systolic function in 1–4 weeks.
Various theories such as catecholamine excess, microvascular dysfunction, neurogenic, and multivessel
coronary artery spasm have been put forward to explain the pathophysiological mechanism behind TTC.
Out of these hypotheses, catecholamine excess is the most studied and favored hypothesis.[2,3]
Catecholamines have been shown to induce myocardial damage by excessive stimulation of cardiac
adrenergic receptors in animal models.[4] Coronary vasospasm is another pathogenic mechanism. It has
been postulated that simultaneous multivessel coronary spasm at the epicardial artery or microvascular
levels may contribute to the onset of Takotsubo such as left ventricular dysfunction.[5] The duration of wall
motion abnormality in TTC is typically longer than would be expected in conventional cases of coronary
vasospasm. Another putative mechanism is neurogenic stunning of the myocardium. This condition is also
observed during acute cerebrovascular accidents and during the catecholamine-induced cardiomyopathy in
patients with pheochromocytoma. Enhanced sympathetic activity appears to play a very important role in
the pathophysiology of TTC. Triggering factors, such as intense emotional stress, are frequently seen in
patients with this syndrome. Excessive levels of catecholamines have been observed in patients with TTC.
[1,2,6,7]
SNRIs such as venlafaxine and duloxetine inhibit the reuptake of catecholamine into the presynaptic neuron,
leaving a net gain in the concentration of epinephrine and serotonin in the synapse, increasing the
probability and frequency of neurotransmitter binding to postsynaptic neurotransmitter receptors.[8,9]
Venlafaxine is sixth most commonly prescribed antidepressant in the US retail market with 17.2 million
prescriptions. Previous studies have shown cardiotoxicity related to venlafaxine including QT prolongation,
heart failure, and arrhythmias.[10] Few case of TTC associated with venlafaxine have been reported, and the
postulated mechanism include block of cardiac fast inwards sodium current resulting in cardiac
conductions[11] and increase in catecholamine levels resulting in myocardial stunning.[11] It has also been
suggested that patients with affective disorders are susceptible to “double whammy” of unusually high
catecholamine response to stress along with greater cardiac sympathetic sensitivity that predisposes these
patients to TTC.[12]
In our literature search on PubMed with “SNRI and Takotsubo” and “venlafaxine and Takotsubo” as
keywords, we could identify 8 more cases of TTC (2 case reports[8,13] and 1 case series[14] with 6
patients). Demographic, clinical characteristic, laboratory characteristics, and imaging findings of all the
patients including our case are summarized in Table 1. Seven out of 9 patients were taking venlafaxine, one
patient was on desvenlafaxine and another patient was on duloxetine when they developed TTC. Most of
these patients were taking prescribed doses of SNRIs (n = 7) whereas two patients had suffered an overdose
of venlafaxine. Eight of the 9 patients were females with mean age of 57.2 years (range 37–82 years). All of
the patients showed segmental left ventricular dysfunction with ejection fraction ranging from 25–60%, and
all of them showed complete recovery of wall motion abnormalities. Eight out of the 9 patients had elevated
troponins on admission (0.10–2.88 ng/ml).
These findings support the theory of apical ballooning caused by catecholamine-induced myocardial
stunning. These patients had elevated serotonin/norepinephrine levels secondary to reuptake inhibition
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leading to TTC. We would emphasize the importance of selectively choosing SNRIs in patients at risk of
TTC. If diagnosed, SNRIs should be stopped and alternate antidepressants should be tried. Moreover,
independent trials evaluating the cardiotoxicity associated with these newer highly selective
serotine/norepinephrine reuptake inhibitors are required.
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Electrocardiogram showing sinus tachycardia at 118/min with diffuse symmetric T wave inversions in limb and precordial
leads but no ST segment changes
Figure 2
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Cardiac catheterization showing normal coronaries. (Panel A) Left ventriculogram in right anterior oblique projection
showing diffuse ballooning of the left ventricular apex in diastole
Figure 3
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(Panel B) Dyskinetic base in systole
Figure 4
Echocardiographgy 4 chamber view showing akinesis and ballooning of the apical segment and hyperactive base of the left
ventricle diastole (Panel B) and systole
Table 1
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Demographic, clinical, laboratory, and clinical characteristics of all the patients
Articles from North American Journal of Medical Sciences are provided here courtesy of Wolters Kluwer --
Medknow Publications
